SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...
Millions of Brits can skip the GP queue this winter and head straight to their local pharmacist. Amid warnings a ‘quad-emic’ of flu, covid, RSV and norovirus, doctors and hospital medics are battling ...
The aggregate gross proceeds to the Company from the offering were approximately $2.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company ...
Clarametyx Biosciences Inc. ("Clarametyx"), a biotechnology company developing immune-enabling biologic technologies to combat serious infections associated with biofilms, today announced that CARB-X ...